Related Experiment Video
Updated: May 10, 2025

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
Published on: November 8, 2016
Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell
Zhenguo Liang1, Hui Xie2, Dongze Wu3
1Department of Rheumatology and Immunology, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, Guangdong, China.
Abstract:
Despite the advancements in targeted biologic therapy for immune-mediated inflammatory diseases (IMIDs), significant challenges persist, including challenges in drug maintenance, primary and secondary non-responses, and adverse effects. Recent data have strengthened the evidence supporting stem cell therapy as an experimental salvage therapy into a standard treatment option. Recent preclinical and clinical studies suggested that chimeric antigen receptor T cell (CAR-T) therapy, which depleting tissue and bone marrow B cells, may lead to improvement, even inducing long-lasting remissions for patients with IMIDs. In this review, we address the unmet needs of targeted biologic therapy, delineate the critical differences between stem cell transplantation and CAR-T therapy, evaluate the current status of CAR-T therapy for IMIDs and explore its potential and existing limitations.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Regulation of Hematopoietic Stem Cells
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
iPS Cell Differentiation
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

